1. Home
  2. AVXL vs BELFB Comparison

AVXL vs BELFB Comparison

Compare AVXL & BELFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • BELFB
  • Stock Information
  • Founded
  • AVXL 2004
  • BELFB 1949
  • Country
  • AVXL United States
  • BELFB United States
  • Employees
  • AVXL N/A
  • BELFB N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • BELFB
  • Sector
  • AVXL Health Care
  • BELFB
  • Exchange
  • AVXL Nasdaq
  • BELFB Nasdaq
  • Market Cap
  • AVXL 794.0M
  • BELFB 865.9M
  • IPO Year
  • AVXL N/A
  • BELFB N/A
  • Fundamental
  • Price
  • AVXL $10.70
  • BELFB $98.02
  • Analyst Decision
  • AVXL Strong Buy
  • BELFB Strong Buy
  • Analyst Count
  • AVXL 2
  • BELFB 4
  • Target Price
  • AVXL $44.00
  • BELFB $100.75
  • AVG Volume (30 Days)
  • AVXL 890.2K
  • BELFB 177.6K
  • Earning Date
  • AVXL 08-05-2025
  • BELFB 07-23-2025
  • Dividend Yield
  • AVXL N/A
  • BELFB 0.28%
  • EPS Growth
  • AVXL N/A
  • BELFB N/A
  • EPS
  • AVXL N/A
  • BELFB 3.42
  • Revenue
  • AVXL N/A
  • BELFB $558,940,000.00
  • Revenue This Year
  • AVXL N/A
  • BELFB $18.21
  • Revenue Next Year
  • AVXL N/A
  • BELFB $7.91
  • P/E Ratio
  • AVXL N/A
  • BELFB $29.04
  • Revenue Growth
  • AVXL N/A
  • BELFB N/A
  • 52 Week Low
  • AVXL $4.00
  • BELFB $58.00
  • 52 Week High
  • AVXL $14.44
  • BELFB $99.60
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 74.00
  • BELFB 75.56
  • Support Level
  • AVXL $9.08
  • BELFB $95.51
  • Resistance Level
  • AVXL $9.78
  • BELFB $98.55
  • Average True Range (ATR)
  • AVXL 0.51
  • BELFB 3.59
  • MACD
  • AVXL 0.14
  • BELFB 0.74
  • Stochastic Oscillator
  • AVXL 93.36
  • BELFB 94.87

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

Share on Social Networks: